ADARx Pharmaceuticals Stock

adarx.comHealthcareFounded: 2019Funding to Date: $152.5MM

ADARx Pharmaceuticals is a company that specializes in genetic medicine designed to treat human diseases and ailments using mRNA transcripts. ADARx researches and develops its therapies through oligonucleotides delivery technology. The firm focuses on three main disease treatments: genetic diseases, cardiometabolic diseases, and central nervous system (CNS) diseases.

Register for Details

For more details on financing and valuation for ADARx Pharmaceuticals, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Enterprise Value (based on primary financings)

Powered by Forge Data
Enterprise Value

View Enterprise Value for ADARx Pharmaceuticals.

Register Today

ADARx Pharmaceuticals investors also invested in these private companies


Management Team

Zhen Li, Ph.D.
President and Chief Executive Officer
Robert A. MacLeod, Ph.D.
Chief Scientific Officer
Chris Prentiss, MBA
Chief Financial Officer

Board Members

Sheila Gujrathi, M.D.
Chair of the Board
Erez Chimovits
Partner OrbiMed Advisors
Simeon George, M.D.
CEO SR One Capital
Carl Gordon, Ph.D., CFA
OrbiMed Advisors
Judith J. Li
Yuan (Eliza) Sun
Sirona Capital

Other companies like ADARx Pharmaceuticals in the Healthcare sector

Last Round Est. Valuation
Last Round Est. Valuation
Last Round Est. Valuation
Last Round Est. Valuation
Last Round Est. Valuation


ADARx Pharmaceuticals is working on an RNA precision medicine platform spanning multiple therapeutic areas.